진매트릭스

본문 바로가기
Search

Innovative Drug Discovery

Development Strategy of novel drugs

by GeneMatrix

Innovative Drug Discovery

We are pursuing the development of new biologics, natural pharmaceutical products and small-molecule drugs through our Protein REFolding enhancER (PREFER) technology, recombinant protein mass production technology, monoclonal antibody screening technology, cell culture technology, and biological efficacy assessment technology.

In particular, we are able to effectively screen and discover drug candidates for biomarker-based targeted therapy, evaluate efficacy, select patient groups for clinical studies, monitor efficacy, and assess effectiveness through our core strengths including the discovery, analysis, and evaluation of biomarkers. We aim to integrate the development of innovative new drugs and the companion diagnostics (CDx) to enable personalized management.

We also intend to strengthen our new drug portfolio through active Connect & Development (C&D). We will continue to dedicate ourselves for exploration, discovery, validation, and development of innovative new drug candidates.

Patent

  • Composition for preventing and treating cancer (Registration No. 10-1361531)
  • Composition containing triticum aestivum lamarck extracts or fraction thereof as an active ingredient (Registration No. 10-1160575)
  • A composition comprising of a sprout extract of Triticum aestivum for treating and preventing obesity disease (Registration No. 10-1277266)
  • A composition for prevention or improvement of nonalcoholic fatty liver disease containing Triticuma estivum extract as an active ingredient
    (Application No. 10-2017-011600)
  • A monoclonal antibody for specifically binding heart-type fatty acid binding protein and hybridoma cell producing the same, and a method for
    preparing the same (Application No. 10-2016-0050308)
  • A Biomarker for Predicting Reactivity with Sorafenib and Use of the Same (Application No. 10-2016-0033879)
  • Composition for anticipating drug resistance against therapeutic agent of chronic Hepatitis B and method thereof
    (Registration No. 10-2012-0035603)
  • Method for predicting the risk of hepato celullar carcinoma occurred in chronic hepatitis B infected patients (Application No. PCT/KR2011/007895)
  • Method for detecting mutations in drug-resistant related genes of HIV using restriction fragments mass polymorphism
    (Application No. PCT/KR2012/002441)
  • Method of prognosis or diagnosis of apoplexy (Application No. 10-2001-005824)
  • Kit for analyzing high-risk HPV gene and method for analyzing the same (Registration No. 10-1401940)

Copyright 2018 © Genematrix Inc., All rights reserved.

Copyrights 2018 ⓒ Genematrix. co.ltd., All rights reserved.